Richard James Whitley

Richard James Whitley (board member) discloses dealings in 2 companies, chiefly Dogwood Therapeutics, Inc. and Gilead Sciences, Inc. Over a trading history stretching from 3 May 2021 to 8 December 2022, the count stands at 6 filings.

Market trades split into 3 purchases (€12k) and 1 sale (€444). Purchases outweigh sales by €12k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 2 option exercises. Since January 2022: 2 purchases and 1 sale on the market.

In size, the median ticket on the buying side is €2,160. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 12 December 2022 with an open-market sale (€444) in Dogwood Therapeutics, Inc. The last insider purchase was made public on 19 May 2022, 1,613 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.